<DOC>
	<DOCNO>NCT00392782</DOCNO>
	<brief_summary>RATIONALE : Giving total-body irradiation chemotherapy , fludarabine thiotepa , donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin remove T cell donor cell transplant may stop happen . PURPOSE : This phase II trial study well donor stem cell transplant work treat patient myeloid cancer disease .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Myeloid Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence disease-free survival 1 year patient acute chronic myeloid leukemia undergo T-cell-depleted hematopoietic stem cell transplantation HLA-C mismatch , unrelated donor . Secondary - Determine incidence disease relapse 1 year patient treat regimen . - Determine incidence severity acute graft-vs-host disease ( GVHD ) 100 day chronic GVHD 1 year patient . - Determine incidence graft failure day 100 . - Determine transplant-related mortality patient 1 year . - Determine overall survival patient 1 year . OUTLINE : This prospective , multicenter study . Patients stratify accord killer-cell immunoglobulin-like receptor ( KIR ) epitope mismatch ( yes [ experimental ] v [ control ] ) . - Myeloablative preparative regimen : Patients undergo total body irradiation twice daily day -10 -9 receive thiotepa intravenously ( IV ) 4 hour day -8 -7 , fludarabine phosphate IV 30-60 minute day -7 -3 , antithymocyte globulin IV 4-6 hour day -5 -2 . - Allogeneic peripheral blood stem cell ( PBSC ) transplantation : Patients undergo filgrastim ( G-CSF ) -mobilized , T-cell-depleted , CD34+-selected allogeneic PBSC transplantation day 0 . After completion study treatment , patient follow periodically least 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Primary acute myeloid leukemia ( AML ) First complete remission ( CR ) high risk feature define : failure achieve remission day 21 induction chemotherapy , presence chromosomal abnormality involve following : 5/de ( 5q ) , 7/del ( 7q ) , inversion 3q , abnormality 11q23 , 20q , 21q , del ( 9q ) , translocation 6 ; 9 , translocation 9 ; 22 , abnormality 17p , complex karyotype &gt; = 3 abnormality . Complete remission define &lt; 5 % blast marrow . Second CR subsequent remission Refractory relapse disease absolute peripheral blood blast &lt; 2000/mcL Secondary AML remission relapse Chronic myelogenous leukemia ( CML ) accelerate blast phase Accelerated phase define one following : Blasts 10 % 19 % peripheral blood white cell bone marrow cell Peripheral blood basophil least 20 % Persistent thrombocytopenia ( &lt; 100 x 10^9/L ) unrelated therapy , persistent thrombocytosis ( &gt; 1000 x 10^9/L ) unresponsive therapy Increasing spleen size increase white blood cell ( WBC ) count unresponsive therapy Cytogenetic evidence clonal evolution ( i.e. , appearance additional genetic abnormality present initial specimen time diagnosis chronic phase CML ) Resistance tyrosine kinase inhibitor ( imatinib ) define complete cytogenetic response even criterion meet . Blast phase define either follow : Blasts 20 % peripheral blood white cell bone marrow cell Extramedullary blast proliferation Large focus cluster blast bone marrow biopsy Primary myelodysplastic syndrome ( MDS ) IPSS score &gt; 1 Secondary MDS international prostate symptom score ( IPSS ) Age â‰¤60 year CoMorbidity score 02 At least 35 day follow start precede leukemia induction therapy Patients suitable HLA genotypically identical sibling fully match HLAA , B , C , DRB1 unrelated donor available . Patients great 60 year age . Hypersensitivity thymoglobulin . Symptomatic uncontrolled coronary artery disease congestive heart failure . Hepatic disease transaminases bilirubin &gt; 2 time upper limit normal ( ULN ) except isolate hyperbilirubinemia attribute Gilbert 's syndrome . Severe hypoxemia room air Partial Pressure Oxygen Arterial Blood ( PAO2 ) &lt; 70 , supplemental oxygendependence , carbon monoxide diffuse capacity ( DLCO ) &lt; 50 % predict . Impaired renal function creatinine &gt; 2 time upper limit normal ( ULN ) creatinine clearance measure 24hour urine collection &lt; 50 % normal age , gender , weight . Patients central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy . Patients human immunodeficiency virus ( HIV ) seropositive . Patients pregnant breastfeeding . Patients active infection untreated , fail respond appropriate therapy . Karnofsky performance status &lt; 50 % . Prior allogeneic autologous bone marrow , peripheral blood stem cell , umbilical cord blood transplant . Inability provide inform consent . Comorbidity score &gt; 2 Less 35 day start previous leukemia induction therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>